Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM).

Bijay Nair, MD, Yazan Alsayed, MD, PhD, Sarah Waheed, MD, Elias Anaissie, MD, PhD, Frits van Rhee, MD, PhD, Jackie Szymonifka, Antje Hoering, Ph.D., John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 531.

https://doi.org/10.1182/blood.V114.22.531.531

Published: 2009

Journal Articles

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., Elias Anaissie, MD, PhD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Sarah Waheed, MD, Bijay Nair, MD, Monica Grazziutti, PhD, Vanessa Bolejack, PhD, John Crowley, PhD

Blood (2009) 114 (22): 744.

https://doi.org/10.1182/blood.V114.22.744.744

Published: 2009

Journal Articles

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Yiming Zhou, Lijuan Chen, Bart Barlogie, MD, PhD, Owen Stephens, PhD, Xiaosong Wu, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, Sarah Waheed, MD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, John D Shaughnessy, Jr.

Blood (2009) 114 (22): 1804.

https://doi.org/10.1182/blood.V114.22.1804.1804

Published: 2009

Journal Articles

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

Sarah Waheed, MD, Yazan Alsayed, MD, PhD, Bijay Nair, MD, Jackie Szymonifka, John D Shaughnessy, Jr., Frits van Rhee, MD, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3421.

https://doi.org/10.1182/blood.V114.22.3421.3421

Published: 2009

Journal Articles

Incidence and Risk Factors for Lower Alimentary Tract Mucositis (neutropenic enterocolitis) Following 1528 Courses of Chemotherapy in a Homogenous Population of Myeloma Patients: Clinical and Research Implications.

Somashekar G Krishna, MD, MPH, Zhao Weizhi, Kavya Krishna, MD, Monica Grazziutti, MD, Bart Barlogie, MD, PhD, Elias Anaissie, MD

Blood (2009) 114 (22): 3343.

https://doi.org/10.1182/blood.V114.22.3343.3343

Published: 2009

Journal Articles

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Michele H. Cottler-Fox, MD, Jeff Haessler, MD, Sarah Waheed, MD, Bijay Nair, MD, John Crowley, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3411.

https://doi.org/10.1182/blood.V114.22.3411.3411

Published: 2009

Journal Articles

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Damir Herman, PhD, Owen Stephens, PhD, Erming Tian, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, Jeffrey Sawyer, Ph.D., John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 250.

https://doi.org/10.1182/blood.V112.11.250.250

Published: 2008

Journal Articles

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Varant Arzoumanian, MD, Bart Barlogie, MD,PhD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, Elias Anaissie, MD, Maurizio Zangari, MD, Somashekar Krishna, MD, Eilas Kiwan, MD, Guido Tricot, MD,PhD, Abid Mohiuddin, MD, Frits van Rhee, MD,PhD

Blood (2006) 108 (11): 3561.

https://doi.org/10.1182/blood.V108.11.3561.3561

Published: 2006

Journal Articles

Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.

Maurizio Zangari, MD, Federica Cavallo, MD, Louis M. Fink, MD, Bart Barlogie, MD, PhD, Vanessa Bolejack, BS, Michael J. Burns, Elias Anaissie, MD, Klaus A. Hollmig, MD, Abid Mohiuddin, MD, Mauricio Pineda-Roman, MD, Guido J. Tricot, MD, PhD

Blood (2006) 108 (11): 3573.

https://doi.org/10.1182/blood.V108.11.3573.3573

Published: 2006

Journal Articles

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Elias Anaissie, MD, Teresa Milner, BS, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 1157.

https://doi.org/10.1182/blood.V106.11.1157.1157

Published: 2005

Journal Articles

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Federica Cavallo, MD, Laurie Jones-Jackson, MD, Elias Anaissie, MD, Terri Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 3493.

https://doi.org/10.1182/blood.V106.11.3493.3493

Published: 2005

Journal Articles

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Choon-Kee Lee, MD, Annick E. Tricot, Athanasios Fassas, MD, Elias Anaissie, MD, Klaus Hollmig, MD, Raymond Thertulien, MD, Giampaolo Talamo, MD, Frits van Rhee, MD, PhD, Julie M. Stover, BA, Louis Fink, MD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4914.

https://doi.org/10.1182/blood.V104.11.4914.4914

Published: 2004

Journal Articles

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampaolo Talamo, MD, Athanasios Fassas, MD, Choon-Kee Lee, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 2399.

https://doi.org/10.1182/blood.V104.11.2399.2399

Published: 2004

Journal Articles

FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls.

Ronald Walker, MD, L. Jones-Jackson, M. Miceli, Elias Anaissie, MD, T. Alpe, R. Walker, Joshua Epstein, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 2473.

https://doi.org/10.1182/blood.V104.11.2473.2473

Published: 2004

Journal Articles

Third Autotransplant for the Management of 98 Patients among 1358 Who Had Received Prior Tandem Autotransplants: Benefit Apparent When 2nd to 3rd Transplant Interval Exceeds 3 Years.

Choon Kee Lee, MD, Bart Barlogie, MD, PhD, Athanasios Fassas, MD, Elias Anaissie, MD, PhD, Maurizio Zangari, MD, Erik Rasmussen, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 540.

https://doi.org/10.1182/blood.V104.11.540.540

Published: 2004

Journal Articles

Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response.

Ronald Walker, MD, L. Jones-Jackson, Eric Rasmussen, M. Miceli, Elias Anaissie, MD, Joshua Epstein, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 758.

https://doi.org/10.1182/blood.V104.11.758.758

Published: 2004

Journal Articles

The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features.

Fenghuang Zhan, PhD, Bart Barlogie, MD, PhD, Yongsheng Huang, PhD, Eric Rasmussen, Jeffrey Sawyer, M. Santra, Ronald Walker, MD, Guido Tricot, MD, PhD, John Crowley, Elias Anaissie, MD, John Shaughnessy, PhD

Blood (2004) 104 (11): 76.

https://doi.org/10.1182/blood.V104.11.76.76

Published: 2004

Journal Articles

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampalamo Talamo, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Frits van Rhee, MD, PhD, Athanasios Fassas, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 929.

https://doi.org/10.1182/blood.V104.11.929.929

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Guido Tricot, MD, PhD, John Crowley, PhD, Julie Stover, BA, Teresa Milner, BS, Athanasios Fassas, MD, Maurizio Zangari, MD, Raymond Thertulien, MD, PhD, Elias Anaissie, MD, Frits van Rhee, MD, PhD, Giampalamo Talamo, MD, Klaus Hollmig, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 936.

https://doi.org/10.1182/blood.V104.11.936.936

Published: 2004

NARROW

Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM).

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

Incidence and Risk Factors for Lower Alimentary Tract Mucositis (neutropenic enterocolitis) Following 1528 Courses of Chemotherapy in a Homogenous Population of Myeloma Patients: Clinical and Research Implications.

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls.

Third Autotransplant for the Management of 98 Patients among 1358 Who Had Received Prior Tandem Autotransplants: Benefit Apparent When 2nd to 3rd Transplant Interval Exceeds 3 Years.

Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response.

The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features.

Addition of Bortezomib (Velcade ™ ) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only